AOTMiT: Transparency Council on insomnia, intimate health and muscular dystrophy, among others

The agenda includes:

1. Prepare a position paper on the qualification of the healthcare benefit Dental treatment of patients with epilepsy through a reinforced denture.

2 Prepare a position paper on the evaluation of the drug Lokelma (Sodium zirconium cyclosilicate) in the indication: treatment of hyperkalemia in adult patients in the course of chronic kidney disease grade 3b-5, in patients taking drugs from the group of inhibitors of the renin-angiotensin-aldosterone system (ACE inhibitors and inhibitors of the receptor for angiotensin.

3 Prepare a position paper on the examination of the appropriateness of issuing reimbursement approvals for the medicinal product Emcitate for the indication: Allan-Herndon-Dudley syndrome.

4 Prepare a position paper to examine the appropriateness of issuing reimbursement approvals for the medicinal product Quviviq (daridorexantum), inorganic insomnia.

5 Prepare a position paper on the examination of the appropriateness of issuing approvals for reimbursement of the medicinal product Dezacor (deflazacort) for the indication: muscular dystrophy of the Duchenne type in the population of pediatric patients.

6 Prepare a position paper on the examination of the legitimacy of issuing approvals for reimbursement of the medicinal product Revestive (teduglutidum) for the indication: short bowel syndrome.

7. Prepare an opinion on the draft health policy program of the local government unit Expanded access to health services for residents of Wroclaw "INTIMATE HEALTH".

Source: AOTMiT